{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:56:03Z","timestamp":1781610963403,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Iron deficiency (ID) and ID anemia (IDA), the most common deficiency diseases, may occur as isolated diseases or secondary to a causative disorder such as menorrhagia, inflammatory bowel disease (IBD), and heart disease (HD). As real-world data are limited, our objective was to assess the prevalence of ID\/IDA, associated comorbidity, drug treatments focusing on trivalent ferric maltol, and healthcare resource utilization (HRU) with associated costs in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This\u00a0retrospective, non-interventional cohort study analyzed anonymized German health claims data covering 2016\u20132021. Data on patients with ID\/IDA and matched control individuals, subgroups of patients with ID\/IDA and concurrent disease (menorrhagia, IBD, HD), as well as patients with ID\/IDA treated with ferric maltol were descriptively analyzed to evaluate prevalences, comorbidities (Elixhauser Comorbidity Index [ECI]), drug prescriptions, HRU, and HRU-associated costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 2021, 129,462 individuals were diagnosed with ID\/IDA. Concurrent menorrhagia, IBD, and HD were observed in 34,421, 8,422, and 44,699 individuals, respectively. ID\/IDA prevalences were stable throughout the study at approximately 3.3% but were higher in older individuals (up to 10.1%) and women of reproductive age (5.6\u20137.35%). Comorbidity burden (ECI) was two-fold higher in patients with ID\/IDA than in control individuals (4.5\u2009\u00b1\u20093.6 vs. 2.3\u2009\u00b1\u20092.5, 2021 [mean\u2009\u00b1\u2009SD]) and increased with concurrent diseases (menorrhagia [3.4\u2009\u00b1\u20092.8], IBD [5.0\u2009\u00b1\u20093.9], HD [7.9\u2009\u00b1\u20093.5]). The most frequently prescribed medication was oral bivalent iron preparation (25.0\u201327.5%; parenteral iron: 5.8\u20136.5%; oral trivalent iron: 0.2\u20130.7%). Ferric maltol dispensations increased slightly from 2018 to 2021 compared to other trivalent iron preparations. In patients with ID\/IDA, the percentages of hospitalizations and sick leaves were higher than in control individuals (41.2% vs. 22.0%; 21.4% vs. 3.1%), corresponding to higher total costs that further increased with concurrent disease. In the subgroup of patients treated with ferric maltol (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009686), HRU was lower in some parameters, with slightly higher ID\/IDA-related total costs. Within 180 days after treatment initiation, most patients continued ferric maltol and did not switch to another iron preparation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the heterogeneity of the disease, monitoring prevalence of ID\/IDA, comorbidities, drug treatments, and HRU may help identify populations at increased health risk to optimize treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-24730-9","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:41:34Z","timestamp":1758710494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epidemiology and treatment of patients with iron deficiency and iron deficiency anemia: a study on longitudinal German health claims data"],"prefix":"10.1186","volume":"25","author":[{"given":"Karina C.","family":"Manz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Stavenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Guillermo Correa","family":"Astorquiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Cengia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuka\u0161in","family":"Vi\u0161kovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"H\u00f6er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mocek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"4 Suppl","key":"24730_CR1","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1177\/15648265030244s206","volume":"24","author":"RJ Stoltzfus","year":"2003","unstructured":"Stoltzfus RJ. Iron deficiency: global prevalence and consequences. Food Nutr Bull. 2003;24(4 Suppl):S99\u2013103. https:\/\/doi.org\/10.1177\/15648265030244s206.","journal-title":"Food Nutr Bull"},{"issue":"4","key":"24730_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1017\/s1368980008002401","volume":"12","author":"E McLean","year":"2009","unstructured":"McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993\u20132005. Public Health Nutr. 2009;12(4):444\u201354. https:\/\/doi.org\/10.1017\/s1368980008002401.","journal-title":"Public Health Nutr"},{"issue":"1","key":"24730_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2018-05-815944","volume":"133","author":"C Camaschella","year":"2019","unstructured":"Camaschella C, Iron deficiency. Blood. 2019;133(1):30\u20139. https:\/\/doi.org\/10.1182\/blood-2018-05-815944.","journal-title":"Blood"},{"key":"24730_CR4","unstructured":"Hastka J, Metzgeroth G, Gattermann N. Eisenmangel und Eisenmangelan\u00e4mie. 2022. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/eisenmangel-und-eisenmangelanaemie\/@@guideline\/html\/index.html. Accessed 17 Oct 2023."},{"issue":"8","key":"24730_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cjco.2023.05.008","volume":"5","author":"BJ MacDonald","year":"2023","unstructured":"MacDonald BJ, Virani SA, Zieroth S, Turgeon R. Heart failure management in 2023: a pharmacotherapy- and lifestyle-focused comparison of current international guidelines. CJC Open. 2023;5(8):629\u201340. https:\/\/doi.org\/10.1016\/j.cjco.2023.05.008.","journal-title":"CJC Open"},{"issue":"2","key":"24730_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/MOG.0b013e32831ef1cd","volume":"25","author":"SF Clark","year":"2009","unstructured":"Clark SF. Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol. 2009;25(2):122\u20138. https:\/\/doi.org\/10.1097\/MOG.0b013e32831ef1cd.","journal-title":"Curr Opin Gastroenterol"},{"issue":"8","key":"24730_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/gut.2003.035758","volume":"53","author":"C Gasche","year":"2004","unstructured":"Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53(8):1190\u20137. https:\/\/doi.org\/10.1136\/gut.2003.035758.","journal-title":"Gut"},{"issue":"14","key":"24730_CR8","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1517\/14656566.2014.953928","volume":"15","author":"Y Beguin","year":"2014","unstructured":"Beguin Y, Jaspers A. Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas. Expert Opin Pharmacother. 2014;15(14):2087\u2013103. https:\/\/doi.org\/10.1517\/14656566.2014.953928.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"24730_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1517\/14656566.2012.669373","volume":"13","author":"M Mu\u00f1oz","year":"2012","unstructured":"Mu\u00f1oz M, Mart\u00edn-Monta\u00f1ez E. Ferric [corrected]arboxymaltose for [corrected]he [corrected]reatment [corrected]f iron-deficiency anemia. [corrected]. Expert Opin Pharmacother. 2012;13(6):907\u201321. https:\/\/doi.org\/10.1517\/14656566.2012.669373.","journal-title":"Expert Opin Pharmacother"},{"key":"24730_CR10","unstructured":"Behnisch W, Muckenthaler M, Kulozik A. S1-Leitlinie Eisenmangelan\u00e4mie. 2021. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/025-021. Accessed 2 November 2023."},{"issue":"12","key":"24730_CR11","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/ibd.20285","volume":"13","author":"C Gasche","year":"2007","unstructured":"Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13(12):1545\u201353. https:\/\/doi.org\/10.1002\/ibd.20285.","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"24730_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/apt.12648","volume":"39","author":"F Gomoll\u00f3n","year":"2014","unstructured":"Gomoll\u00f3n F, Chowers Y, Danese S, Dignass A, Haagen Nielsen O, Lakatos PL, et al. Letter: European medicines agency recommendations for allergic reactions to intravenous iron-containing medicines. Aliment Pharmacol Ther. 2014;39(7):743\u20134. https:\/\/doi.org\/10.1111\/apt.12648.","journal-title":"Aliment Pharmacol Ther"},{"key":"24730_CR13","doi-asserted-by":"publisher","first-page":"846824","DOI":"10.1100\/2012\/846824","volume":"2012","author":"P Santiago","year":"2012","unstructured":"Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. ScientificWorldJournal. 2012;2012:846824. https:\/\/doi.org\/10.1100\/2012\/846824.","journal-title":"ScientificWorldJournal"},{"issue":"3","key":"24730_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/mib.0000000000000314","volume":"21","author":"C Gasche","year":"2015","unstructured":"Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, B\u00fcning C, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21(3):579\u201388. https:\/\/doi.org\/10.1097\/mib.0000000000000314.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"24730_CR15","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/0006-2952(88)90556-4","volume":"37","author":"JA Levey","year":"1988","unstructured":"Levey JA, Barrand MA, Callingham BA, Hider RC. Characteristics of iron(III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol. Biochem Pharmacol. 1988;37(10):2051\u20137. https:\/\/doi.org\/10.1016\/0006-2952(88)90556-4.","journal-title":"Biochem Pharmacol"},{"key":"24730_CR16","unstructured":"European Medicines Agency. Feraccru. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/feraccru. Accessed 17 Nov 2023."},{"key":"24730_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57\u201362. https:\/\/doi.org\/10.1016\/j.puhe.2022.02.013.","journal-title":"Public Health"},{"key":"24730_CR18","unstructured":"Federal Institute for Drugs and Medical Devices. OPS (German procedure classification [Operationen- und Prozedurenschl\u00fcssel]). 2023. https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/OPS-ICHI\/OPS\/_node.html. Accessed 11 November 2023."},{"issue":"11","key":"24730_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1055\/a-0795-3319","volume":"81","author":"M Schwendler","year":"2019","unstructured":"Schwendler M, Fle\u00dfa S. [The calculated physician\u2019s fee in the doctor\u2019s fee scale (EBM): A normative parameter for medical Doctors in the outpatient sector]. Gesundheitswesen. 2019;81(11):919\u201325. https:\/\/doi.org\/10.1055\/a-0795-3319.","journal-title":"Gesundheitswesen"},{"key":"24730_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy9010060","author":"S Hollingworth","year":"2021","unstructured":"Hollingworth S, Kairuz T. Measuring medicine use: applying ATC\/DDD methodology to real-world data. Pharmacy (Basel). 2021. https:\/\/doi.org\/10.3390\/pharmacy9010060.","journal-title":"Pharmacy (Basel)"},{"key":"24730_CR21","unstructured":"Federal Institute for Drugs and Medical Devices. International Statistical Classification of Diseases, German Modification. 2022. https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/ICD\/ICD-10-GM\/_node.html. Accessed 12 Jul 2023."},{"issue":"3","key":"24730_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10654-019-00500-x","volume":"34","author":"W Hoffmann","year":"2019","unstructured":"Hoffmann W, Latza U, Baumeister SE, Br\u00fcnger M, Buttmann-Schweiger N, Hardt J, et al. Guidelines and recommendations for ensuring good epidemiological practice (GEP): a guideline developed by the German society for epidemiology. Eur J Epidemiol. 2019;34(3):301\u201317. https:\/\/doi.org\/10.1007\/s10654-019-00500-x.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"24730_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0034-1396815","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, et al. Gute praxis sekund\u00e4rdatenanalyse (GPS): Leitlinien und empfehlungen. Gesundheitswesen. 2015;77(2):120\u20136. https:\/\/doi.org\/10.1055\/s-0034-1396815.","journal-title":"Gesundheitswesen"},{"key":"24730_CR24","unstructured":"Federal Statistical Office. Current population of Germany. 2021. https:\/\/www.destatis.de\/EN\/Themes\/Society-Environment\/Population\/Current-Population\/_node.html. Accessed 12 Oct 2023."},{"issue":"1","key":"24730_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327. https:\/\/doi.org\/10.1097\/00005650-199801000-00004.","journal-title":"Med Care"},{"issue":"12","key":"24730_CR26","doi-asserted-by":"publisher","first-page":"e0143365","DOI":"10.1371\/journal.pone.0143365","volume":"10","author":"J Stausberg","year":"2015","unstructured":"Stausberg J, Hagn S. New morbidity and comorbidity scores based on the structure of the ICD-10. PLoS ONE. 2015;10(12):e0143365. https:\/\/doi.org\/10.1371\/journal.pone.0143365.","journal-title":"PLoS ONE"},{"issue":"11","key":"24730_CR27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"key":"24730_CR28","unstructured":"Federal Statistical Office. Consumer price index. 2019. https:\/\/www.destatis.de\/EN\/Themes\/Economy\/Prices\/Consumer-Price-Index\/_node.html. Accessed 12 Oct 2023."},{"key":"24730_CR29","unstructured":"The R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2022. https:\/\/www.r-project.org\/. Accessed 17 Oct 2023."},{"issue":"5","key":"24730_CR30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.tjnut.2023.03.012","volume":"153","author":"M Cooper","year":"2023","unstructured":"Cooper M, Bertinato J, Ennis JK, Sadeghpour A, Weiler HA, Dorais V. Population iron status in Canada: results from the Canadian health measures survey 2012\u20132019. J Nutr. 2023;153(5):1534\u201343. https:\/\/doi.org\/10.1016\/j.tjnut.2023.03.012.","journal-title":"J Nutr"},{"issue":"3","key":"24730_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.tjnut.2022.10.011","volume":"153","author":"VC Chang","year":"2023","unstructured":"Chang VC, Cotterchio M, Kotsopoulos J, Bondy SJ. Iron status and associated factors among Canadian women: results from the Canadian health measures survey. J Nutr. 2023;153(3):781\u201397. https:\/\/doi.org\/10.1016\/j.tjnut.2022.10.011.","journal-title":"J Nutr"},{"issue":"37","key":"24730_CR32","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.3346\/jkms.2023.38.e299","volume":"38","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Pak H, Han JJ, Chang MH. Comprehensive analysis of iron deficiency anemia and its related disorders in premenopausal women based on a propensity score matching case control study using National health insurance service database in Korea. J Korean Med Sci. 2023;38(37):e299. https:\/\/doi.org\/10.3346\/jkms.2023.38.e299.","journal-title":"J Korean Med Sci"},{"issue":"Suppl 4","key":"24730_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/anae.15405","volume":"76","author":"CS Benson","year":"2021","unstructured":"Benson CS, Shah A, Stanworth SJ, Frise CJ, Spiby H, Lax SJ, et al. The effect of iron deficiency and anaemia on women\u2019s health. Anaesthesia. 2021;76(Suppl 4):84\u201395. https:\/\/doi.org\/10.1111\/anae.15405.","journal-title":"Anaesthesia"},{"issue":"1","key":"24730_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/asheducation-2017.1.152","volume":"2017","author":"C Breymann","year":"2017","unstructured":"Breymann C, Auerbach M. Iron deficiency in gynecology and obstetrics: clinical implications and management. Hematology. 2017;2017(1):152\u20139. https:\/\/doi.org\/10.1182\/asheducation-2017.1.152.","journal-title":"Hematology"},{"issue":"8","key":"24730_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3109\/00016349309021150","volume":"72","author":"N Milman","year":"1993","unstructured":"Milman N, Rosdahl N, Lyhne N, J\u00f8rgensen T, Graudal N. Iron status in Danish women aged 35\u201365 years. Relation to menstruation and method of contraception. Acta Obstet Gynecol Scand. 1993;72(8):601\u20135. https:\/\/doi.org\/10.3109\/00016349309021150.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"5","key":"24730_CR36","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1016\/s2214-109x(18)30185-2","volume":"6","author":"MF Young","year":"2018","unstructured":"Young MF. Maternal anaemia and risk of mortality: a call for action. Lancet Glob Health. 2018;6(5):e479\u201380. https:\/\/doi.org\/10.1016\/s2214-109x(18)30185-2.","journal-title":"Lancet Glob Health"},{"key":"24730_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/nu12113594","author":"C Portugal-Nunes","year":"2020","unstructured":"Portugal-Nunes C, Castanho TC, Amorim L, Moreira PS, Mariz J, Marques F, et al. Iron status is associated with mood, cognition, and functional ability in older adults: a cross-sectional study. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12113594.","journal-title":"Nutrients"},{"key":"24730_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.mad.2018.07.003","volume":"175","author":"AA Wawer","year":"2018","unstructured":"Wawer AA, Jennings A, Fairweather-Tait SJ. Iron status in the elderly: a review of recent evidence. Mech Ageing Dev. 2018;175:55\u201373. https:\/\/doi.org\/10.1016\/j.mad.2018.07.003.","journal-title":"Mech Ageing Dev"},{"issue":"5","key":"24730_CR39","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/ehf2.12797","volume":"7","author":"VK Chopra","year":"2020","unstructured":"Chopra VK, Anker SD. Anaemia, iron deficiency and heart failure in 2020: facts and numbers. ESC Heart Fail. 2020;7(5):2007\u201311. https:\/\/doi.org\/10.1002\/ehf2.12797.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"24730_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","volume":"165","author":"IT Klip","year":"2013","unstructured":"Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575\u2013e823. https:\/\/doi.org\/10.1016\/j.ahj.2013.01.017.","journal-title":"Am Heart J"},{"issue":"7","key":"24730_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/17474124.2021.1900730","volume":"15","author":"Y Shah","year":"2021","unstructured":"Shah Y, Patel D, Khan N. Iron deficiency anemia in IBD: an overlooked comorbidity. Expert Rev Gastroenterol Hepatol. 2021;15(7):771\u201381. https:\/\/doi.org\/10.1080\/17474124.2021.1900730.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"24730_CR42","doi-asserted-by":"publisher","first-page":"e026186","DOI":"10.1136\/bmjopen-2018-026186","volume":"9","author":"ME Schoep","year":"2019","unstructured":"Schoep ME, Adang EMM, Maas JWM, De Bie B, Aarts JWM, Nieboer TE. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open. 2019;9(6):e026186. https:\/\/doi.org\/10.1136\/bmjopen-2018-026186.","journal-title":"BMJ Open"},{"issue":"10021","key":"24730_CR43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/s0140-6736(15)60865-0","volume":"387","author":"A Lopez","year":"2016","unstructured":"Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387(10021):907\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(15)60865-0.","journal-title":"Lancet"},{"issue":"3","key":"24730_CR44","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjh.17202","volume":"193","author":"D Rund","year":"2021","unstructured":"Rund D. Intravenous iron: do we adequately understand the short- and long-term risks in clinical practice? Br J Haematol. 2021;193(3):466\u201380. https:\/\/doi.org\/10.1111\/bjh.17202.","journal-title":"Br J Haematol"},{"issue":"3","key":"24730_CR45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.12669\/pjms.323.9799","volume":"32","author":"C Gereklioglu","year":"2016","unstructured":"Gereklioglu C, Asma S, Korur A, Erdogan F, Kut A. Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pak J Med Sci. 2016;32(3):604\u20137. https:\/\/doi.org\/10.12669\/pjms.323.9799.","journal-title":"Pak J Med Sci"},{"issue":"4","key":"24730_CR46","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00006250-199404000-00013","volume":"83","author":"KJ Carlson","year":"1994","unstructured":"Carlson KJ, Miller BA, Fowler FJ Jr. The Maine women\u2019s health study: II. outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol. 1994;83(4):566\u201372. https:\/\/doi.org\/10.1097\/00006250-199404000-00013.","journal-title":"Obstet Gynecol"},{"issue":"12","key":"24730_CR47","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","volume":"49","author":"DB Van Wyck","year":"2009","unstructured":"Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12):2719\u201328. https:\/\/doi.org\/10.1111\/j.1537-2995.2009.02327.x.","journal-title":"Transfusion"},{"issue":"6","key":"24730_CR48","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1590\/s0102-311x2009000600005","volume":"25","author":"AI Souza","year":"2009","unstructured":"Souza AI, Batista Filho M, Bresani CC, Ferreira LO, Figueiroa JN. Adherence and side effects of three ferrous sulfate treatment regimens on anemic pregnant women in clinical trials. Cad Saude Publica. 2009;25(6):1225\u201333. https:\/\/doi.org\/10.1590\/s0102-311x2009000600005.","journal-title":"Cad Saude Publica"},{"issue":"2","key":"24730_CR49","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1060028020941014","volume":"55","author":"A Khoury","year":"2021","unstructured":"Khoury A, Pagan KA, Farland MZ. Ferric maltol: a new oral iron formulation for the treatment of iron deficiency in adults. Ann Pharmacother. 2021;55(2):222\u20139. https:\/\/doi.org\/10.1177\/1060028020941014.","journal-title":"Ann Pharmacother"},{"key":"24730_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-000530","author":"JF Cummings","year":"2021","unstructured":"Cummings JF, Fraser A, Stansfield C, Beales I, Sebastian S, Hoque S. Ferric maltol real-world effectiveness study in hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK. BMJ Open Gastroenterol. 2021. https:\/\/doi.org\/10.1136\/bmjgast-2020-000530.","journal-title":"BMJ Open Gastroenterol"},{"issue":"11","key":"24730_CR51","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671\u20136. https:\/\/doi.org\/10.3324\/haematol.2014.111492.","journal-title":"Haematologica"},{"issue":"4","key":"24730_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","volume":"105","author":"Drug allergy","year":"2010","unstructured":"Drug allergy. An updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259\u201373.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-24730-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:36:59Z","timestamp":1781609819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-24730-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24730"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-24730-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In Germany, the use of social data for scientific research is regulated by the SGB X (Social Security Code X). However, all patient- and provider-level data in the InGef research database are anonymized and are no longer social data in the sense of \u00a7\u00a067 para. 2 SGB X (Social Security Code X) in combination with Art. 4 Nr. 1 GDPR (General Data Protection Regulation) and as such are no longer subject to these regulations. The use of the study database for this study was therefore fully compliant with legal and regulatory requirements. Since anonymized administrative claims data were used and presented only in aggregate form, informed consent of patients was not required. The pre-existing database did not allow direct identification of patients, and no contact was made with patients. This study was conducted in accordance with research practices described in the Good Epidemiological Practice (GEP) guidelines of the German Society for Epidemiology (DGEpi) [22] and in accordance with the guidelines and recommendations described in the Good Practice of Secondary Data Analysis (GPS) of the Working Group for the Survey and Utilisation of Secondary Data (AGENS) of the German Society for Social Medicine and Prevention (DGSMP) and the German Society for Epidemiology (DGEpi) [23]. Accordingly, a consultation with an ethics committee was not required because the analyses were based exclusively on secondary data.\u00a0The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not contain patient-identifiable data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DM is an employee of Norgine Ltd. FS is an employees of Norgine GmbH. LGCA is an employee of Norgine de Espa\u00f1a S. L. U.\u00a0KCM and AH are employees of the IGES Institut GmbH, which is a paid consultant to Norgine Ltd. for conducting the study and preparing the manuscript. At the time of this study, AM was an employee of the IGES Institut GmbH.\u00a0AC and VV are employees of InGef \u2013 Institute for Applied Health Research Berlin GmbH, which was contracted and reimbursed by IGES Institut GmbH for providing the data and carrying out the analyses.\u00a0As such the authors are either direct employees of Norgine, the funder of this study, or have acted as consultants or sub-contractors on the project. Norgine is the rights holder of FERACCRU\u00ae (ferric maltol), which was partly a focal point of this investigation. The design of the study, which focuses partly on Norgine's product, has been influenced by funding from Norgine. While the authors assert that this funding did not impact the conduct of the study, the interpretation of the results, and the right to publish the results without limitation, the focus on ferric maltol reflects the interests of the funding source. The authors have not included comparative analyses of other iron deficiency treatments in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3053"}}